Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
- Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival…